Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label Study of Safety and Efficacy of Quisinostat in Combination With Paclitaxel + Carboplatin Chemotherapy in Patients With Metastatic or Locally Advanced Epithelial Ovarian Cancer, Primarily Peritoneal or Fallopian Tube Carcinoma, Resistant to First Line Platinum and Paclitaxel Based Chemotherapy

NCT02948075 is registered in ClinicalTrials.gov with NewVac LLC as lead sponsor.

NCT NCT02948075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02948075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label Study of Safety and Efficacy of Quisinostat in Combination With Paclitaxel + Carboplatin Chemotherapy in Patients With Metastatic or Locally Advanced Epithelial Ovarian Cancer, Primarily Peritoneal or Fallopian Tube Carcinoma, Resistant to First Line Platinum and Paclitaxel Based Chemotherapy
Lead sponsor
NewVac LLC
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2015
Completion date
June 16, 2017
Enrollment
31 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer